Assertio Holdings, Inc. 8-K

What Happened

• Assertio Holdings, Inc. announced it completed an asset sale on April 8, 2026, selling its rights to six product franchises — INDOCIN®, SPRIX®, SYMPAZAN®, CAMBIA®, ZIPSOR® and the recently decommercialized OTREXUP® — to Cosette Pharmaceuticals, Inc.
• The transaction closed under an Asset Purchase Agreement and delivered $35,000,000 in cash to Assertio, with additional contingent/deferred payments possible based on future milestones and SPRIX performance. Assertio also filed unaudited pro forma condensed consolidated financial statements (Exhibit 99.1) reflecting the sale.

Key Details

• Purchase price: $35,000,000 cash at closing.
• Additional potential consideration:
  • Up to $32,000,000 in aggregate net sales–based milestones for SYMPAZAN, INDOCIN and OTREXUP.
  • For SPRIX: (a) $1,000,000 one‑time payment if new batch quality approval and delivery to Cosette’s warehouse occurs by May 31, 2026; (b) 8% of SPRIX gross profits from April 8, 2026 through December 31, 2027; (c) $2,000,000 one‑time payment if SPRIX net sales exceed $7,000,000 in calendar year 2027.
• Cosette assumed certain contracts, liabilities and obligations related to the Products, including manufacturing/supply, post‑market commitments and clinical development costs.
• Assertio provided pro forma financial statements as of December 31, 2025 and for fiscal years 2025 and 2024 to show the transaction’s accounting impact (unaudited, not predictive).

Why It Matters

• The deal immediately monetizes multiple legacy product franchises, providing Assertio $35M in cash up front and potential upside through earnouts and profit sharing tied to SPRIX.
• By transferring the products and related obligations to Cosette, Assertio reduces ongoing manufacturing, post‑market and development liabilities tied to these franchises, which can affect future operating costs and risk exposure.
• Investors should consider the effects on Assertio’s revenue mix and future cash flows: near‑term cash boost versus removal of these product revenue streams and the limited contingent upside from earnouts and SPRIX profit sharing. The company’s pro forma financials reflect these changes for investor analysis.